Cefixime

ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Cefixime is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1989. DrugCentral lists 4 molecular targets, including ska, PLCG1 and DRD2. Recorded indications include Acute bacterial bronchitis, Acute exacerbation of chronic bronchitis, Acute gonococcal cervicitis and Acute gonococcal urethritis.

• Approval status: ofp (first approved 1989 by the FDA).
• Molecular targets: ska, PLCG1, DRD2 and mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB (4 listed in DrugCentral).
• Indications: Acute bacterial bronchitis, Acute exacerbation of chronic bronchitis, Acute gonococcal cervicitis, Acute gonococcal urethritis and Acute otitis media and others.
• ATC code: J01DD08 (Third-generation cephalosporins).
• Molecular formula: C16H15N5O7S2; molecular weight 453.46 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (22)

• Acute bacterial bronchitis
• Acute exacerbation of chronic bronchitis
• Acute gonococcal cervicitis
• Acute gonococcal urethritis
• Acute otitis media
• Bronchitis
• Escherichia coli urinary tract infection
• Gonorrhea
• Haemophilus Influenzae Acute Otitis Media
• Haemophilus Influenzae Bronchitis
• Haemophilus Influenzae Chronic Bronchitis
• Infective otitis media
• Moraxella Catarrhalis Acute Otitis Media
• Pharyngitis
• Proteus urinary tract infection
• Streptococcal tonsillitis
• Streptococcus Pneumoniae Bronchitis
• Streptococcus Pneumoniae Chronic Bronchitis
• Streptococcus pyogenes infection
• Tonsillitis
• Upper respiratory infection
• Urinary tract infectious disease

Off-label uses (4)

• Acute bacterial sinusitis
• Haemophilus Parahaemolyticus Pneumonia
• Haemophilus Parainfluenzae Pneumonia
• Pneumonia due to Escherichia coli

Contraindications (2)

• Impaired renal function disorder
• Pseudomembranous enterocolitis

Mechanism & targets

Molecular targets (4)

Target	Gene	Action	Activity
Streptokinase A	ska	unknown	EC50 7.22
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1	PLCG1	unknown	IC50 5.92
D(2) dopamine receptor	DRD2	unknown	IC50 4.24
Bacterial penicillin-binding protein	mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1989-04-28	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
J01DD08	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Third-generation cephalosporins
J01DD58	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Third-generation cephalosporins
J01RA15	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › COMBINATIONS OF ANTIBACTERIALS › Combinations of antibacterials
J01RA16	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › COMBINATIONS OF ANTIBACTERIALS › Combinations of antibacterials

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Macular degeneration	89.5
Clostridium difficile colitis	63.4
Pulmonary congestion	55.9
Secretion discharge	53.7
Toxic epidermal necrolysis	51.8
Clostridium difficile infection	44.8
Erythema	44.2
Pneumonia mycoplasmal	44.0
Gastroenteritis staphylococcal	41.7
Stevens-Johnson syndrome	41.4
Oropharyngeal gonococcal infection	40.4
Biopsy colon abnormal	39.8

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Cefixime is on its molecule page.

• Molecular formula: C₁₆H₁₅N₅O₇S₂
• Molecular weight: 453.46 g/mol
• CAS number: —
• InChIKey: OKBVVJOGVLARMR-QSWIMTSFSA-N
• PubChem CID: 5362065

NC1=NC(=CS1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cefixime used for?

DrugCentral lists the following indications for Cefixime: Acute bacterial bronchitis, Acute exacerbation of chronic bronchitis, Acute gonococcal cervicitis, Acute gonococcal urethritis, Acute otitis media, Bronchitis, Escherichia coli urinary tract infection and Gonorrhea and others.

How does Cefixime work?

Its molecular targets in DrugCentral include ska, PLCG1, DRD2 and mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB (inhibitor).

When was Cefixime first approved?

Cefixime was first approved by the FDA in 1989.

What is the chemical formula of Cefixime?

Cefixime has the molecular formula C16H15N5O7S2 and a molecular weight of 453.46 g/mol.

Sources

• DrugCentral drug card 537 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1541 — compound record and bioactivity
• PubChem CID 5362065 — chemical identifiers
• DrugBank DB00671 — drug record
• FDA UNII 97I1C92E55 — substance identity
• DailyMed: FDA labels for Cefixime — current prescribing information (label search)
• UniProt P19174 (PLCG1) — target protein
• UniProt P14416 (DRD2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.